严重的死性气管支气管炎是由B型流感和甲素耐药黄金葡萄球菌联合感染引起的,在一个免疫能力强的患者身上
Shu Wang1, Jianhua Yang1, Wenwu Sun2
1Department of Intensive Care Medicine, Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing, 400016, China.
在一个免疫能力强的患者中,严重的死性气管支气管炎是由B型流感和耐甲基西林黄金葡萄球菌 (MRSA) 的同时感染引起的. 及时诊断和有针对性的治疗导致了成功的恢复.
科学领域:
- 传染性疾病 传染性疾病
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
背景情况:
- 死性气管支气管炎是一种罕见的炎症状况,影响气管和支气管.
- 同时感染可能导致严重的呼吸系统疾病,特别是在免疫能力强的个体.
研究的目的:
- 报告一种由B型流感和抗甲素黄金葡萄球菌 (MRSA) 共感染引起的严重死性气管支气管炎病例.
- 强调在这种情况下及时诊断和治疗的重要性.
主要方法:
- 一个36岁的男性病例呈现,病情迅速恶化.
- 诊断工具包括支气管镜检查,CT成像,下一代测序 (NGS) 和支气管支气管洗液 (BALF) 培养.
- 治疗包括抗病毒药物,万科米辛和支持性护理.
主要成果:
- 确认了与流感B和MRSA的同时感染.
- 观察到严重的死性气管支气管炎与肺腔化.
- 证明了T和NK淋巴细胞功能的暂时抑制.
- 在治疗后,呼吸道和肺部病变显著改善.
- 成功的患者康复和恢复淋巴细胞功能.
结论:
- 在患有B型流感和快速呼吸衰退的患者中,应考虑结核性气管支气管炎.
- 早期发现并发感染对于有效管理至关重要.
- 适当的抗生素和抗病毒疗法是成功结果的关键.
更多相关视频
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
08:01Imaging Cell Interaction in Tracheal Mucosa During Influenza Virus Infection Using Two-photon Intravital Microscopy
Published on: August 17, 2018
相关概念视频
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
